<p>McAdam LLC 在最近向证券交易委员会提交的文件中表示，在第一季度将其在 Vertex Pharmaceuticals Incorporated（纳斯达克：VRTX - 免费报告）的持股减少了 76.5%。该基金在此期间出售了 1,679 股后，持有该制药公司 516 股股票。McAdam LLC 在 Vertex Pharmaceuticals 的持股在最近一个季度末价值 25 万美元。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p>其他几家机构投资者和对冲基金最近也买卖了该公司的股票。Activest Wealth Management 在第一季度新购入了约 25,000 美元的 Vertex Pharmaceuticals 股份。Clal Insurance Enterprises Holdings Ltd 在第一季度将其在 Vertex Pharmaceuticals 的持股增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 现在拥有 55 股该制药公司的股票，价值约 27,000 美元，此前在上个季度又购买了 45 股。Mascagni Wealth Management Inc.在第四季度新购入了约 31,000 美元的 Vertex Pharmaceuticals 股份。Flaharty Asset Management LLC 在第一季度新购入了约 32,000 美元的 Vertex Pharmaceuticals 股份。最后，Mpwm Advisory Solutions LLC 在第四季度新购入了约 40,000 美元的 Vertex Pharmaceuticals 股份。目前，90.96% 的股票由机构投资者和对冲基金持有。</p>
<p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
<h2>Vertex Pharmaceuticals 的内部活动</h2>
<p>在其他 Vertex Pharmaceuticals 的新闻中，董事 Bruce I. Sachs 于 8 月 6 日星期三购买了 5,000 股 Vertex Pharmaceuticals 的股票。该股票的平均购买成本为每股 389.68 美元，总价值为 1,948,400.00 美元。收购完成后，该董事持有该公司 45,000 股股票，价值约 17,535,600 美元。这代表了他们持股的 12.50% 的增长。此次购买在向证券交易委员会的文件中披露，可以通过此超链接访问。内部人士持有该公司 0.20% 的股票。</p>
<h2>Vertex Pharmaceuticals 的价格表现</h2>
<ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
<p>VRTX 的股票在周五开盘价为 397.37 美元。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 362.50 美元，1 年最高价为 519.88 美元。该股票的市值为 1,018.8 亿美元，市盈率为 28.40，贝塔值为 0.44。该公司 50 日移动平均价格为 423.87 美元，200 日移动平均价格为 454.15 美元。</p>
<p>Vertex Pharmaceuticals（纳斯达克：VRTX - 获取免费报告）最近一次公布财报是在 8 月 4 日星期一。该制药公司报告季度每股收益为 4.52 美元，超出分析师一致预期的 4.24 美元，超出幅度为 0.28 美元。Vertex Pharmaceuticals 的净利润率为 31.86%，股本回报率为 23.91%。该公司在本季度的收入为 29.4 亿美元，而分析师预期为 29 亿美元。在去年同期，该公司每股收益为（12.83）美元。与去年同期相比，该公司的收入增长了 11.3%。Vertex Pharmaceuticals 已将其 2025 财年的指导目标设定为每股收益。整体而言，股票分析师预计 Vertex Pharmaceuticals Incorporated 在当前财年将发布 15.63 美元的每股收益。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Vertex 的止痛药：大型制药公司的下一个重大成功？</li>
</ul>
<p>一些分析师最近对 VRTX 股票发布了报告。Raymond James Financial 在 9 月 2 日星期二开始对 Vertex Pharmaceuticals 的股票进行覆盖。他们对该公司的评级为 “市场表现”。Truist Financial 在 8 月 5 日星期二对 Vertex Pharmaceuticals 设定了 490.00 美元的目标价，并给予该股票 “买入” 评级。摩根大通将 Vertex Pharmaceuticals 的目标价从 515.00 美元上调至 517.00 美元，并在 7 月 14 日星期一的报告中给予该公司 “增持” 评级。BMO 资本市场在 8 月 5 日星期二的研究报告中对 Vertex Pharmaceuticals 设定了 530.00 美元的目标价，并给予该股票 “跑赢大盘” 评级。最后，Erste Group Bank 在 5 月 23 日星期五的研究报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “持有”。一位研究分析师对该股票给予了 “强烈买入” 评级，十四位分析师给予 “买入” 评级，十三位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 496.05 美元。</p>
<p><strong>查看我们关于 Vertex Pharmaceuticals 的最新报告</strong></p>
<h2>Vertex Pharmaceuticals 公司简介</h2>
<p>（免费报告）</p>
<p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更喜欢的五只股票胜过 Vertex Pharmaceuticals</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>接近阻力的高飞股票：3 只值得关注的股票</li>
<li>3 只可以提升您投资组合的家居改善股票</li>
<li>希捷科技引领标准普尔 500：其 120% 涨幅背后的原因是什么？</li>
<li>纽约证券交易所的股票为投资者提供多种优质选择</li>
<li>先锋的 VUG ETF：您投资组合的终极增长 ETF</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
<p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛市场注意到之前立即购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
<p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

福泰制药

<p>McAdam LLC 在第一季度将其在 Vertex Pharmaceuticals (NASDAQ:VRTX) 的持股减少了 76.5%，目前持有 516 股，价值 250,000 美元。其他机构投资者也调整了他们的持仓。董事 Bruce I. Sachs 以每股 389.68 美元购买了 5,000 股，增加了 12.5% 的持股比例。Vertex 的股票开盘价为 397.37 美元，市值为 1,018.8 亿美元，市盈率为 28.40。该公司报告了上个季度每股收益为 4.52 美元，超出预期，并已设定 2025 财年的每股收益指引。分析师对该股票的评级不一，普遍目标价为 496.05 美元</p>

<p>McAdam LLC decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 76.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 516 shares of the pharmaceutical company's stock after selling 1,679 shares during the period. McAdam LLC's holdings in Vertex Pharmaceuticals were worth $250,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>McAdam LLC 在最近向证券交易委员会提交的文件中表示，在第一季度将其在 Vertex Pharmaceuticals Incorporated（纳斯达克：VRTX - 免费报告）的持股减少了 76.5%。该基金在此期间出售了 1,679 股后，持有该制药公司 516 股股票。McAdam LLC 在 Vertex Pharmaceuticals 的持股在最近一个季度末价值 25 万美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p>Several other institutional investors and hedge funds also recently bought and sold shares of the company. Activest Wealth Management acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $25,000. Clal Insurance Enterprises Holdings Ltd increased its holdings in shares of Vertex Pharmaceuticals by 450.0% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company's stock worth $27,000 after buying an additional 45 shares during the last quarter. Mascagni Wealth Management Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $31,000. Flaharty Asset Management LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $32,000. Finally, Mpwm Advisory Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $40,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他几家机构投资者和对冲基金最近也买卖了该公司的股票。Activest Wealth Management 在第一季度新购入了约 25,000 美元的 Vertex Pharmaceuticals 股份。Clal Insurance Enterprises Holdings Ltd 在第一季度将其在 Vertex Pharmaceuticals 的持股增加了 450.0%。Clal Insurance Enterprises Holdings Ltd 现在拥有 55 股该制药公司的股票，价值约 27,000 美元，此前在上个季度又购买了 45 股。Mascagni Wealth Management Inc.在第四季度新购入了约 31,000 美元的 Vertex Pharmaceuticals 股份。Flaharty Asset Management LLC 在第一季度新购入了约 32,000 美元的 Vertex Pharmaceuticals 股份。最后，Mpwm Advisory Solutions LLC 在第四季度新购入了约 40,000 美元的 Vertex Pharmaceuticals 股份。目前，90.96% 的股票由机构投资者和对冲基金持有。</p>
</div><p>Get <strong>Vertex Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Vertex Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Insider Activity at Vertex Pharmaceuticals</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的内部活动</h2>
</div><p>In other Vertex Pharmaceuticals news, Director Bruce I. Sachs bought 5,000 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company's stock, valued at approximately $17,535,600. This represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Insiders own 0.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Vertex Pharmaceuticals 的新闻中，董事 Bruce I. Sachs 于 8 月 6 日星期三购买了 5,000 股 Vertex Pharmaceuticals 的股票。该股票的平均购买成本为每股 389.68 美元，总价值为 1,948,400.00 美元。收购完成后，该董事持有该公司 45,000 股股票，价值约 17,535,600 美元。这代表了他们持股的 12.50% 的增长。此次购买在向证券交易委员会的文件中披露，可以通过此超链接访问。内部人士持有该公司 0.20% 的股票。</p>
</div><h2>Vertex Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 的价格表现</h2>
</div><ul>
<li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li>
</ul>
<div class="lb-trans"><ul>
<li>MaxCyte：构建细胞和基因治疗创新的未来</li>
</ul>
</div><p>Shares of VRTX opened at $397.37 on Friday. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $519.88. The stock has a market cap of $101.88 billion, a PE ratio of 28.40 and a beta of 0.44. The firm has a fifty day moving average price of $423.87 and a 200 day moving average price of $454.15.</p>
<div class="lb-trans"><p>VRTX 的股票在周五开盘价为 397.37 美元。Vertex Pharmaceuticals Incorporated 的 1 年最低价为 362.50 美元，1 年最高价为 519.88 美元。该股票的市值为 1,018.8 亿美元，市盈率为 28.40，贝塔值为 0.44。该公司 50 日移动平均价格为 423.87 美元，200 日移动平均价格为 454.15 美元。</p>
</div><p>Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The business had revenue of $2.94 billion during the quarter, compared to analysts' expectations of $2.90 billion. During the same period in the prior year, the company earned ($12.83) earnings per share. The business's revenue was up 11.3% compared to the same quarter last year. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals（纳斯达克：VRTX - 获取免费报告）最近一次公布财报是在 8 月 4 日星期一。该制药公司报告季度每股收益为 4.52 美元，超出分析师一致预期的 4.24 美元，超出幅度为 0.28 美元。Vertex Pharmaceuticals 的净利润率为 31.86%，股本回报率为 23.91%。该公司在本季度的收入为 29.4 亿美元，而分析师预期为 29 亿美元。在去年同期，该公司每股收益为（12.83）美元。与去年同期相比，该公司的收入增长了 11.3%。Vertex Pharmaceuticals 已将其 2025 财年的指导目标设定为每股收益。整体而言，股票分析师预计 Vertex Pharmaceuticals Incorporated 在当前财年将发布 15.63 美元的每股收益。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Vertex's Pain Drug: Big Pharma's Next Major Success?</li>
</ul>
<div class="lb-trans"><ul>
<li>Vertex 的止痛药：大型制药公司的下一个重大成功？</li>
</ul>
</div><p>A number of analysts have recently issued reports on VRTX shares. Raymond James Financial started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a &#34;market perform&#34; rating for the company. Truist Financial set a $490.00 price target on shares of Vertex Pharmaceuticals and gave the stock a &#34;buy&#34; rating in a report on Tuesday, August 5th. JPMorgan Chase &amp; Co. lifted their target price on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, July 14th. BMO Capital Markets set a $530.00 target price on shares of Vertex Pharmaceuticals and gave the stock an &#34;outperform&#34; rating in a research note on Tuesday, August 5th. Finally, Erste Group Bank downgraded shares of Vertex Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, May 23rd. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and thirteen have issued a Hold rating to the company's stock. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $496.05.</p>
<div class="lb-trans"><p>一些分析师最近对 VRTX 股票发布了报告。Raymond James Financial 在 9 月 2 日星期二开始对 Vertex Pharmaceuticals 的股票进行覆盖。他们对该公司的评级为 “市场表现”。Truist Financial 在 8 月 5 日星期二对 Vertex Pharmaceuticals 设定了 490.00 美元的目标价，并给予该股票 “买入” 评级。摩根大通将 Vertex Pharmaceuticals 的目标价从 515.00 美元上调至 517.00 美元，并在 7 月 14 日星期一的报告中给予该公司 “增持” 评级。BMO 资本市场在 8 月 5 日星期二的研究报告中对 Vertex Pharmaceuticals 设定了 530.00 美元的目标价，并给予该股票 “跑赢大盘” 评级。最后，Erste Group Bank 在 5 月 23 日星期五的研究报告中将 Vertex Pharmaceuticals 的评级从 “强烈买入” 下调至 “持有”。一位研究分析师对该股票给予了 “强烈买入” 评级，十四位分析师给予 “买入” 评级，十三位分析师对该公司的股票给予 “持有” 评级。根据 MarketBeat 的数据，Vertex Pharmaceuticals 目前的平均评级为 “适度买入”，共识目标价为 496.05 美元。</p>
</div><p><strong>View Our Latest Report on Vertex Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Vertex Pharmaceuticals 的最新报告</strong></p>
</div><h2>Vertex Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Vertex Pharmaceuticals 公司简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.</p>
<div class="lb-trans"><p>Vertex Pharmaceuticals Incorporated 是一家生物技术公司，专注于开发和商业化治疗囊性纤维化（CF）的疗法。它为至少有一个 F508del 突变的 2 岁或以上的 CF 患者销售 TRIKAFTA/KAFTRIO；为 6 岁或以上的 CF 患者销售 SYMDEKO/SYMKEVI；为 1 岁或以上的 CF 患者销售 ORKAMBI；以及为 1 岁或以上的 CF 患者销售 KALYDECO。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Vertex Pharmaceuticals</li>
<li>What is a Secondary Public Offering? What Investors Need to Know</li>
<li>High-Flyers Near Resistance: 3 Stocks to Watch for a Dip</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>Seagate Technology Leads S&amp;P 500: What’s Behind Its 120% Gain?</li>
<li>NYSE Stocks Give Investors a Variety of Quality Options</li>
<li>Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更喜欢的五只股票胜过 Vertex Pharmaceuticals</li>
<li>什么是二次公开募股？投资者需要知道什么</li>
<li>接近阻力的高飞股票：3 只值得关注的股票</li>
<li>3 只可以提升您投资组合的家居改善股票</li>
<li>希捷科技引领标准普尔 500：其 120% 涨幅背后的原因是什么？</li>
<li>纽约证券交易所的股票为投资者提供多种优质选择</li>
<li>先锋的 VUG ETF：您投资组合的终极增长 ETF</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlJUWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=VRTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Vertex Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Vertex Pharmaceuticals 吗？</h2>
</div><p>Before you consider Vertex Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Vertex Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vertex Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛市场注意到之前立即购买……而 Vertex Pharmaceuticals 并不在名单上。</p>
</div><p>While Vertex Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Vertex Pharmaceuticals 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

McAdam LLC 出售了福泰制药公司 $VRTX 的股票